Kornitzer Capital Management Inc. KS lowered its position in shares of Repligen Co. (NASDAQ:RGEN) by 9.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 233,120 shares of the biotechnology company’s stock after selling 23,490 shares during the quarter. Kornitzer Capital Management Inc. KS owned approximately 0.53% of Repligen worth $12,929,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Repligen by 6.2% in the third quarter. BlackRock Inc. now owns 6,212,759 shares of the biotechnology company’s stock valued at $344,558,000 after acquiring an additional 361,598 shares during the period. OppenheimerFunds Inc. grew its stake in Repligen by 7.4% in the second quarter. OppenheimerFunds Inc. now owns 2,135,929 shares of the biotechnology company’s stock valued at $100,473,000 after acquiring an additional 146,290 shares during the period. Conestoga Capital Advisors LLC grew its stake in Repligen by 13.4% in the third quarter. Conestoga Capital Advisors LLC now owns 1,941,212 shares of the biotechnology company’s stock valued at $107,660,000 after acquiring an additional 230,080 shares during the period. Macquarie Group Ltd. grew its stake in Repligen by 12.3% in the second quarter. Macquarie Group Ltd. now owns 1,107,691 shares of the biotechnology company’s stock valued at $52,106,000 after acquiring an additional 121,157 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Repligen by 5.6% in the third quarter. Dimensional Fund Advisors LP now owns 1,073,887 shares of the biotechnology company’s stock valued at $59,556,000 after acquiring an additional 57,067 shares during the period. Institutional investors and hedge funds own 94.72% of the company’s stock.
Several research analysts have recently weighed in on the company. ValuEngine raised Repligen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 23rd. HC Wainwright reaffirmed a “hold” rating and set a $60.00 price objective on shares of Repligen in a research report on Monday, November 5th. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research report on Thursday, October 4th. BidaskClub cut Repligen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 25th. Finally, JPMorgan Chase & Co. increased their price target on Repligen from $60.00 to $70.00 and gave the company an “overweight” rating in a research report on Friday, November 2nd. Four equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. Repligen presently has a consensus rating of “Buy” and a consensus price target of $62.60.
Shares of NASDAQ RGEN opened at $64.67 on Monday. Repligen Co. has a 52 week low of $29.56 and a 52 week high of $70.50. The company has a market cap of $2.84 billion, a P/E ratio of 93.72, a P/E/G ratio of 5.07 and a beta of 0.69.
Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.18 by $0.02. Repligen had a return on equity of 5.39% and a net margin of 12.61%. The firm had revenue of $49.53 million during the quarter, compared to analysts’ expectations of $46.69 million. During the same period in the prior year, the firm posted $0.15 earnings per share. The business’s quarterly revenue was up 35.4% compared to the same quarter last year. Equities analysts predict that Repligen Co. will post 0.73 EPS for the current fiscal year.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.